 Akcea Therapeutics, Inc. NASDAQ: AKCA, a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the Main Association of Austrian Social Security Institutions Dachverband der Österreichischen Sozialversicherungsträger, or DV has granted approval for the national reimbursement of TEGSEDI inotersen for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin hATTR amyloidosis. 